PIRS News and Press, Pieris Pharmaceuticals Inc. From 05/17/21

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT PRS-060/AZD1402 dosed to first patient in phase 2a study Cinrebafusp alfa (PRS-343) phase 2 study expected to begin this summer Announced license and collaboration agreement with Boston Pharmaceuti...

BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced th...

Pieris Pharmaceuticals (PIRS) and Boston Pharmaceuticals have brokered a licensing agreement for the development of PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology bispecific fusion protein.Under the terms of the deal, Pieris will receive an upfront payment of $10M and up to $353M in milest...

Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties Boston Pharmaceuticals will be primarily responsible for development of the program, with both parties collaborating during the investigational new drug (IND)-enabling ...

Penny Stocks To Buy According To Analysts Whether you love penny stocks or hate them, you can’t argue with the fact that big money can be made. By definition, the term itself references stocks to buy for less than $5. So even the slightest 50 cent move from the highest-priced pen...

Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa Durable anti-tumor activity in heavily pre-treated patient population ​including "cold" and HER2-low expressing t...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...

Pieris Pharmaceuticals, Inc (PIRS) Q4 2020 Earnings Conference Call March 30, 2021, 08:00 AM ET Company Participants Tom Bures - VP, Finance Steve Yoder - President and CEO Hitto Kaufmann - Chief Scientific Officer Shane Olwill - SVP and Head, Translational Science Conference Call Participant...

Pieris Pharmaceuticals (PIRS): FY GAAP EPS of -$0.68 in-line.Revenue of $29.32M (-36.6% Y/Y) misses by $0.85M.Shares +6% PM.Press Release For further details see: Pieris Pharmaceuticals EPS in-line, misses on revenue

Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves $13 million milestone from AstraZeneca for initiation of PRS-060/AZD1402 phase 2a study and AstraZeneca to purchase $10 million equity stake in Pieris common stock as part of an amende...